Prognosis of Primary Melanoma

Ilmonen, Suvi; Asko‐Seljavaara, Sirpa; Al, Kariniemi; Jeskanen, Leila; Pyrhönen, Seppo; Muhonen, Timo

doi:10.1177/145749690209100206

Cited by 11 publications

(9 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The international data for incidence and mortality for prostate cancer also vary by ethnic group [2,3]; prostate cancer incidence and mortality rates among Black American men are higher than any other racial groups in the US and about twice those in White American men [4,5]. Blacks in the US are also more likely to present with advanced prostate cancer.…”

Section: Introductionmentioning

confidence: 98%

Ethnic differences in prostate cancer survival in New Zealand: a national study

Sneyd

2008

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 98%

Ethnic differences in prostate cancer survival in New Zealand: a national study

Sneyd

2008

Cancer Causes Control

View full text Add to dashboard Cite

show abstract

“…Several clinical and routine histological factors of primary melanomas with prognostic significance have been described, that is, tumor thickness according to Breslow, Clark levels, ulceration, localization, presence of tumor-infiltrating lymphocytes, gender, and patients' age. 1 By far, the most significant and consistent prognostic factor in all series over the past 20 years is Breslow thickness of the primary melanoma. 2 Kanitakis et al 3 have recently found that CD10 is more frequently expressed in metastatic than in primary melanoma.…”

mentioning

confidence: 99%

CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression

et al. 2004

View full text Add to dashboard Cite

CD10 antigen is a 100-kDa-cell surface zinc metalloendopeptidase expressed in a variety of normal and neoplastic lymphoid and nonlymphoid tissues including melanomas. It was recently shown that metastatic melanomas express more CD10 than primary tumors. We evaluated CD10 expression in tumor and stromal cells in 70 biopsies with primary and 28 with metastatic malignant melanomas. Ki-67, Bcl-2, and Bax were also examined to investigate whether CD10 expression is associated with tumor proliferation index or factors of apoptosis. Formalin-fixed/paraffin-embedded tissues were studied by immunohistochemistry. More advanced primary tumors had higher CD10 expression in the tumor cells (r ¼ 0.27, P ¼ 0.03 for Clark levels and r ¼ 0.29, P ¼ 0.02 for Breslow) and higher Ki-67 proliferation fraction (r ¼ 0.32, P ¼ 0.007 for Clark levels and r ¼ 0.32, P ¼ 0.001 for Breslow). Similarly, CD10 expression in the intratumoral stromal cells was also higher in primary tumors with higher Clark level (P ¼ 0.04, linear-by-linear association) and tumor thickness according to Breslow (r ¼ 0.33, P ¼ 0.01). The presence of CD10 þ peritumoral stromal cell cuffs was also positively associated with tumor thickness according to Breslow (r ¼ 0.27, P ¼ 0.05). Also, expression of CD10 and Ki-67 were significantly higher in metastatic than in primary tumors (P ¼ 0.01 and 0.02 respectively), but Bcl-2 expression was higher in primary melanomas (P ¼ 0.02). We conclude that CD10 expression in malignant melanoma is associated with tumor progression.

show abstract

“…In the early 1990 s, surgical margins diminished to 1-3 cm, and elective lymphadenectomy was less frequent [11]. Earlier, the radical operation required up to 5 cm margins, and high-risk patients also underwent elective lymphadenectomy.…”

Section: Excision Of Primary Melanoma and Management Of Lymph Nodesmentioning

confidence: 99%

Outcome following local recurrence or in-transit metastases in cutaneous melanoma

Suojärvi

Jahkola

Virolainen³

et al. 2012

Melanoma Research

View full text Add to dashboard Cite

Defining clinical factors influencing outcome after local recurrence or in-transit metastasis may help us to improve treatment and develop follow-up guidelines. A retrospective review of melanoma patients with local recurrence in the primary tumor scar or with in-transit metastasis was carried out. Outcome and survival were analyzed for 99 patients. In univariate analysis, factors related to overall survival following local recurrence at the time of the first relapse were initial stage [P=0.002, hazard ratio (HR) 1.9], site of primary tumor (P=0.02, HR 1.1), Breslow thickness (P=0.002, HR 1.2), Clark classification (P=0.01, HR 1.7), ulceration (P=0.01, HR 2.1), presence of satellite tumor (P=0.03, HR 2.7), and development of lymph node or distant metastases during follow-up (P<0.001, HR 7.0). Local recurrence within 2 years after surgery of primary melanoma correlated with worse survival (P=0.02, HR 2.1). Patients with local recurrence as first relapse often have a poor prognosis if the disease recurs within 2 years after primary surgery.

show abstract

Prognosis of Primary Melanoma

Abstract: We conclude that the prognosis of primary melanoma has improved in Finland in the last decades being in line with a global tendency.

Cited by 11 publications

References 19 publications

Ethnic differences in prostate cancer survival in New Zealand: a national study

Ethnic differences in prostate cancer survival in New Zealand: a national study

CD10 protein expression in tumor and stromal cells of malignant melanoma is associated with tumor progression

Outcome following local recurrence or in-transit metastases in cutaneous melanoma

Contact Info

Product

Resources

About